Compounders sue over the semaglutide shortage delisting

The Outsourcing Facilities Association has challenged the FDA's declaratory order that ended the official semaglutide shortage, a decision the agency made on February 21, 2025 ^[1]. Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, had been on the FDA's 506e shortage list since 2022 ^[1]. Once the agency removed it, compounding pharmacies and outsourcing facilities were told they had a limited window to stop producing versions that are "essentially a copy" of the brand-name drugs ^[1].

The FDA set two deadlines. Smaller 503A compounding pharmacies got 60 days, until April 22, 2025, to stop compounding, distributing, and dispensing copycat semaglutide ^[1]. Larger 503B outsourcing facilities, which produce compounded drugs in bulk, got 90 days, until May 22, 2025 ^[1]. The grace period covers not just making the drug, but also distributing and dispensing it, which creates complications for pharmacies that had stockpiled product in anticipation of continued shortages ^[1].

In its order, the FDA said it looked beyond data from Novo Nordisk, the maker of brand-name semaglutide products ^[1]. The agency said it also considered information from telehealth companies, pharmacy compounders, trade associations representing compounders and outsourcing facilities, and individual patients and providers ^[1]. Even so, the FDA concluded that this outside information did not show Novo Nordisk would be unable to meet demand once compounding was curtailed, especially when weighed against the company's own data ^[1]. The agency acknowledged that "significant compounding of semaglutide injection products is occurring" and that some patients using compounded versions would likely seek out Novo Nordisk's approved products once compounding stopped ^[1].

The FDA's action on semaglutide is separate from an ongoing legal fight over tirzepatide, the active ingredient in Mounjaro and Zepbound, according to a February 25 analysis from law firm Frier Levitt ^[1]. That case, Outsourcing Facilities Association v. FDA, was filed in October 2024 in federal court in Texas and centers on a preliminary injunction motion tied to tirzepatide's own shortage removal ^[1]. The tirzepatide grace period remains dependent on how the district court rules in that case ^[1].

Why it matters for patients

Patients who have been getting compounded semaglutide, often through telehealth platforms, may see that option disappear on the FDA's timeline unless the lawsuit changes the outcome ^[1]. Compounded versions have often been cheaper or easier to obtain than brand-name Ozempic, Wegovy, or Rybelsus, so a legal loss for compounders could push some patients back toward FDA-approved products or leave them searching for alternatives ^[1].

The FDA has said it will keep monitoring supply and demand, and pharmacies that still have trouble getting brand-name product from wholesalers are supposed to keep reporting those shortages to the agency ^[1]. That means the situation could shift again if real shortages resurface, even though the official 506e listing has been removed ^[1].

The legal dispute also raises questions the FDA itself has not fully answered, according to Frier Levitt, including whether the agency has authority to regulate pharmacy dispensing, a function usually overseen by state boards of pharmacy ^[1]. How courts resolve that question could affect how strictly the compounding limits are enforced.

What happens next

The 60-day grace period for 503A pharmacies is set to end April 22, 2025, and the 90-day period for 503B outsourcing facilities is set to end May 22, 2025 ^[1]. It is not yet known from available sources how the Outsourcing Facilities Association's lawsuit over the semaglutide order will be resolved, or whether a court will pause enforcement the way it may in the separate tirzepatide case ^[1]. Frier Levitt noted that other industry groups may also challenge the FDA's semaglutide determination, since the legal basis differs from the tirzepatide dispute ^[1].